NTLA
NASDAQ · Biotechnology
Intellia Therapeutics Inc
$15.67
+0.47 (+3.09%)
Financial Highlights (FY 2026)
Revenue
91.63M
Net Income
-558,808,175
Gross Margin
—
Profit Margin
-609.9%
Rev Growth
+9.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 47.2% | 47.2% |
| Operating Margin | -651.7% | -586.5% | -16.3% | -17.5% |
| Profit Margin | -609.9% | -579.4% | -13.6% | -13.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 91.63M | 83.99M | 223.20M | 196.34M |
| Gross Profit | — | — | 105.32M | 92.65M |
| Operating Income | -597,112,871 | -492,622,223 | -36,318,767 | -34,359,138 |
| Net Income | -558,808,175 | -461,020,586 | -30,251,127 | -26,608,774 |
| Gross Margin | — | — | 47.2% | 47.2% |
| Operating Margin | -651.7% | -586.5% | -16.3% | -17.5% |
| Profit Margin | -609.9% | -579.4% | -13.6% | -13.6% |
| Rev Growth | +9.1% | +9.1% | +19.1% | +20.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 735.97M | 562.69M |
| Total Equity | — | — | 1.00B | 1.02B |
| D/E Ratio | — | — | 0.73 | 0.55 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -583,901,715 | -508,485,314 | -52,265,042 | -37,903,322 |
| Free Cash Flow | — | — | -47,461,783 | -26,029,407 |